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https://ourworldindata.org/causes-of-death
Patients with lung
cancer have 89% 
increased risk of CAD
In older breast cancer
survivors CVD is the
leading cause of death
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Case 1: María Pilar
68 years old female.
2008: Left breast cancer: 
Surgery+radiotherapy+5y tamoxifen.
2016: Bilateral breast cancer:
QT: doxorubicina-ciclofosfamida---taxol-
trastuzumab. Letrozol
Surgery: Bilateral mastectomy+right axilar 
linfadenectomy
RT: 50Gy right thorax and right axila
Sept 2017: ends trastuzumab
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Effort dyspnea since May 2017:
Mild anaemia and Radiotherapy pneumonitis
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-EARLY DETECTION
-EARLY TREATMENT




Enalapril (11±7 mg/d) 36%
Enalapril (12±6 mg/d) + Carvedilol (14 ±7 mg/d)
201 anthracycline treated patients
LVEF≤ 45%
36 ±27 months follow-up
-Responders: LVEF>50%
-Partial responders: improvement
LVEF≥10%, but LVEF <50%
-Non-responders
Enalapril and carvedilol
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DIFFERENT ENTITIES, DIFFERENT PROGNOSIS
INCIDENT DIAGNOSIS OF BREAST CANCER INCIDENT DIAGNOSIS OF HEART FAILURE
>50% MORTALITY AT 5 YEARS
<20% MORTALITY AT 5 YEARS
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THEY ARE THE SAME PATIENTS
>50% MORTALITY AT 5 YEARS
<20% MORTALITY AT 5 YEARS
INCIDENT DIAGNOSIS OF BREAST CANCER INCIDENT DIAGNOSIS OF HEART FAILURE
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Shared risk factors
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Incidence of left ventricular dysfunction associated with 
chemotherapy drugs
ESC Position Paper. Eur J Heart Failure 2017. 
Madrid, December 1st 2018
T. López –Férnandez et al.  Rev Esp Cardiol 2017
Medication ralated risk
-High risk: Anthracyclines, Cyclophosphamide, Trastuzumab, Carfilzomib
-Intermediate risk: Docetaxel, Pertuzumab, Sunitinib, Sorafinib
-Low risk: Bevacizumab, Dasatimib, Imatinib, Lapatinib
Myocardyal dysfunction risk
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34 years old
No cardiovascular risk factors
2000: Hodgkin lymphoma treated with QT chest
RT.
2018: 3 month effort angina.
Case 2: Fernando
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Radiotherapy induced cardiotoxicity
-Cellular damage
- High chest doses, > 30Gy: 
Hodgkin lymphoma, breast cancer
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64 years old
Previous smoker more than 30 years ago, hypertension
treated with enalapril 20 mg/d for the last 10 years.
Sept 2018: Three month effort dyspnea: Recent
diagnosis of Lung adenocarcimona stage IV with
moderate pericardial effusion and no haemodynamic
compromise.
Starts treatment with carboplatin-permetrexed.
October 2018: Left calf muscle pain: left limb deep vein
thrombosis. Starts low molecular heparin treatment
Case 3: José Luis
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Take-home messages
• With many shared modifiable risk factors, 
cancer and CVD often coexist in the same 
individuals.
• Chemotherapy, radiotherapy and 
inmunotherapy have potential 
cardiotoxicity.
• Cardio-Oncologist: Past, Present and Future
